Phuong Khanh Morrow - May 23, 2023 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
Chief Medical Officer
Signature
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
Stock symbol
CRSP
Transactions as of
May 23, 2023
Transactions value $
-$166,555
Form type
4
Date filed
5/25/2023, 05:35 PM
Previous filing
Mar 14, 2023
Next filing
Oct 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRSP Common Shares Options Exercise +6.94K 6.94K May 23, 2023 Direct F1, F2
transaction CRSP Common Shares Tax liability -$167K -2.53K -36.42% $65.91 4.41K May 24, 2023 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Restricted Stock Units Options Exercise +6.94K +50.01% 20.8K May 23, 2023 Common Shares 6.94K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restriced stock units shall vest as follows: (i) one quarter of the shares shall vest on May 23, 2023, (ii) one quarter of the shares shall vest on May 23, 2024, (iii) one quarter of the shares shall vest on May 23, 2025, and (iv) one quarter of the shares shall vest on May 23, 2026.
F2 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F3 On May 23, 2022, the reporting person was granted 27,750 restricted stock units. On May 23, 2023, 6,938 restricted stock units vested. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.